JPMorgan Chase & Co. Decreases Holdings in Compass Therapeutics, Inc. $CMPX

JPMorgan Chase & Co. reduced its position in Compass Therapeutics, Inc. (NASDAQ:CMPX) by 5.9% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 1,999,278 shares of the company’s stock after selling 126,439 shares during the period. JPMorgan Chase & Co. owned approximately 1.12% of Compass Therapeutics worth $6,997,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of CMPX. Victory Capital Management Inc. boosted its position in Compass Therapeutics by 20.6% in the third quarter. Victory Capital Management Inc. now owns 12,652 shares of the company’s stock worth $44,000 after purchasing an additional 2,164 shares during the last quarter. Focus Partners Wealth increased its position in shares of Compass Therapeutics by 16.2% during the 3rd quarter. Focus Partners Wealth now owns 15,805 shares of the company’s stock valued at $56,000 after purchasing an additional 2,206 shares during the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of Compass Therapeutics by 1.9% in the 3rd quarter. Dimensional Fund Advisors LP now owns 175,556 shares of the company’s stock worth $619,000 after purchasing an additional 3,329 shares during the period. Russell Investments Group Ltd. lifted its stake in shares of Compass Therapeutics by 3,933.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 7,785 shares of the company’s stock worth $27,000 after purchasing an additional 7,592 shares during the period. Finally, Alps Advisors Inc. boosted its holdings in shares of Compass Therapeutics by 11.3% in the third quarter. Alps Advisors Inc. now owns 83,007 shares of the company’s stock worth $291,000 after buying an additional 8,410 shares during the last quarter. Institutional investors own 68.43% of the company’s stock.

Analysts Set New Price Targets

CMPX has been the topic of several recent research reports. D. Boral Capital reiterated a “buy” rating and issued a $30.00 price target on shares of Compass Therapeutics in a research report on Tuesday, January 6th. Guggenheim restated a “buy” rating and issued a $12.00 price objective on shares of Compass Therapeutics in a research note on Tuesday, March 24th. Raymond James Financial reaffirmed an “outperform” rating on shares of Compass Therapeutics in a report on Thursday, March 5th. Citizens Jmp set a $10.00 target price on Compass Therapeutics in a research report on Wednesday, December 3rd. Finally, Citigroup began coverage on Compass Therapeutics in a report on Wednesday, December 3rd. They set an “outperform” rating for the company. One analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Compass Therapeutics has a consensus rating of “Moderate Buy” and an average price target of $13.45.

Compass Therapeutics Stock Performance

Shares of NASDAQ:CMPX opened at $5.29 on Wednesday. The firm has a market cap of $952.68 million, a price-to-earnings ratio of -12.30 and a beta of 1.48. The firm has a fifty day moving average price of $5.87 and a 200 day moving average price of $5.06. Compass Therapeutics, Inc. has a fifty-two week low of $1.33 and a fifty-two week high of $6.88.

Compass Therapeutics (NASDAQ:CMPX) last announced its quarterly earnings results on Thursday, March 5th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.01. As a group, research analysts predict that Compass Therapeutics, Inc. will post -0.36 earnings per share for the current year.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.